These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34303369)

  • 1. Cerebral localization of chronic myelomonocytic leukemia: a case report.
    Haméon C; Rousselot C; Arbion F; Cibron J; Cottier JP; Destrieux C; Hérault O; Gyan E
    J Med Case Rep; 2021 Jul; 15(1):368. PubMed ID: 34303369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral localization of chronic myelomonocytic leukemia and improvement with high-dose cytarabine: A case report.
    Haméon C; Machet A; Drieu La Rochelle L; Vallet N; Lejeune J; Ravalet N; Cottier JP; Hérault O; Gyan E
    EJHaem; 2023 Aug; 4(3):844-847. PubMed ID: 37601847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.
    Courville EL; Wu Y; Kourda J; Roth CG; Brockmann J; Muzikansky A; Fathi AT; de Leval L; Orazi A; Hasserjian RP
    Mod Pathol; 2013 Jun; 26(6):751-61. PubMed ID: 23307061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleural effusion heralds acute leukemic transformation of chronic myelomonocytic leukemia.
    Huang CT; Kuo PH; Yao M; Tsai YJ; Yang PC
    South Med J; 2008 Dec; 101(12):1279-80. PubMed ID: 19005440
    [No Abstract]   [Full Text] [Related]  

  • 5. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
    Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
    Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
    Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
    Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
    Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
    Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and meta
    Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
    Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
    Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two cases of acute myeloid leukemia evolving into a chronic myelomonocytic leukemia-like state after induction therapy.
    Iwama A; Miwa A; Suzuki T; Komatsu N; Yoshida M; Suda T; Sakamoto S; Miura Y
    Intern Med; 1992 Feb; 31(2):214-7. PubMed ID: 1600270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unilateral testicular mass in man with chronic myelomonocytic leukemia: unusual presentation of chronic myelomonocytic leukemia sequela.
    Corcoran NM; Tsui A; Costello AJ; Bouchier-Hayes D
    Urology; 2005 May; 65(5):1001. PubMed ID: 15882745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A 45-year-old man with peripheral monocytosis and right hemiparesis].
    Takubo H; Hattori N; Irie S; Mizutani Y; Mori H; Suda K; Kondo T; Oshimi K; Mizuno Y
    No To Shinkei; 1998 May; 50(5):481-9. PubMed ID: 9621375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
    Michaux JL; Martiat P
    Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.
    Zandberg DP; Huang TY; Ke X; Baer MR; Gore SD; Smith SW; Davidoff AJ
    Haematologica; 2013 Apr; 98(4):584-90. PubMed ID: 23144192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoid pneumonia with chronic myelomonocytic leukemia.
    Itoh Y; Segawa H; Kito K; Hodohara K; Ishigaki H; Sugihara H; Fujiyama Y; Ogasawara K
    Pathol Res Pract; 2009; 205(2):143-7. PubMed ID: 18805647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
    Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
    Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
    Kenealy M; Patton N; Filshie R; Nicol A; Ho SJ; Hertzberg M; Mills T; Prosser I; Link E; Cowan L; Zannino D; Seymour JF
    Leuk Lymphoma; 2017 Feb; 58(2):298-307. PubMed ID: 27268068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.